These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12791408)

  • 21. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group.
    Am J Kidney Dis; 1991 Jul; 18(1):50-9. PubMed ID: 2063855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosage individualization of erythropoietin using a profile-dependent support vector regression.
    Martín-Guerrero JD; Camps-Valls G; Soria-Olivas E; Serrano-López AJ; Pérez-Ruixo JJ; Jiménez-Torres NV
    IEEE Trans Biomed Eng; 2003 Oct; 50(10):1136-42. PubMed ID: 14560766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Erythropoietin in renal anemia].
    Peña Amaro MP; García López J; Camacho Romera M
    Rev Enferm; 1992 Mar; 15(163):67-70. PubMed ID: 1565973
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
    Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
    Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of subcutaneous low-dose erythropoietin in patients with chronic renal failure despite functional iron deficiency.
    Bedani PL; Cecchetti E; Gilli P
    Nephron; 1995; 71(4):459-60. PubMed ID: 8587628
    [No Abstract]   [Full Text] [Related]  

  • 26. Recombinant human erythropoietin: physiology, pathophysiology of anemia in renal failure, and economic aspects related to dosing.
    Besarab A
    Am J Nephrol; 1990; 10 Suppl 2():2-6. PubMed ID: 2260613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-weekly epoetin-beta in renal anemia: the clinical evidence.
    Albertazzi A
    Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986
    [No Abstract]   [Full Text] [Related]  

  • 28. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 29. Correction of copper deficiency improves erythropoietin unresponsiveness in hemodialysis patients with anemia.
    Higuchi T; Matsukawa Y; Okada K; Oikawa O; Yamazaki T; Ohnishi Y; Fujita T; Fukuda N; Soma M; Matsumoto K
    Intern Med; 2006; 45(5):271-3. PubMed ID: 16595992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human erythropoietin for anemia of end-stage renal failure in beta thalassemia trait.
    Kagan A; Sinay-Trieman L; Bar-Khayim Y
    Nephron; 1992; 62(2):229-30. PubMed ID: 1436320
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin.
    Adamson JW; Eschbach JW
    Annu Rev Med; 1990; 41():349-60. PubMed ID: 2184735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoietin: issues in its use as a therapeutic for the anemia of chronic renal failure.
    Eschbach JW; Adamson JW
    Blood Purif; 1990; 8(5):239-54. PubMed ID: 2091684
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of renal anemia with recombinant human erythropoietin.
    Schaefer RM; Hörl WH; Massry SG
    Am J Nephrol; 1989; 9(5):353-62. PubMed ID: 2679093
    [No Abstract]   [Full Text] [Related]  

  • 34. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.
    Boran M; Dalva I; Yazicioğlu A; Cetin S
    Nephron; 1993; 63(1):113-4. PubMed ID: 8446239
    [No Abstract]   [Full Text] [Related]  

  • 35. Erythropoietin use in a Jehovah's Witness patient.
    Walton T; Macon EJ
    Ann Pharmacother; 2002 Apr; 36(4):729-30. PubMed ID: 11936087
    [No Abstract]   [Full Text] [Related]  

  • 36. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin.
    Eschbach JW
    Kidney Int; 1989 Jan; 35(1):134-48. PubMed ID: 2651751
    [No Abstract]   [Full Text] [Related]  

  • 37. [Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis].
    Wanic-Kossowska M; Kazmierski M; Pawliczak E; Kobelski M
    Pol Arch Med Wewn; 2007; 117(1-2):14-9. PubMed ID: 17642201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model predictive control of erythropoietin administration in the anemia of ESRD.
    Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
    Am J Kidney Dis; 2008 Jan; 51(1):71-9. PubMed ID: 18155535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human erythropoietin (rHuEPO) in the treatment of anaemia of chronic renal failure.
    Desai JD; Shah BV
    J Assoc Physicians India; 1991 Jun; 39(6):483-5. PubMed ID: 1938855
    [No Abstract]   [Full Text] [Related]  

  • 40. Gain in recombinant human erythropoietin dosage with continuous intravenous intradialytic administration for the treatment of anaemia in end-stage renal disease.
    Liani M; Salvati F; Golato M; Cahen R
    Nephron; 1995; 69(2):189. PubMed ID: 7723913
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.